Aline Renneville

List of Publications by Year
in descending order

158 papers	9,212 citations	41258 49 h-index	40881 93 g-index
165 all docs	165 docs citations	165 times ranked	10381 citing authors

#	Article	IF	Citations
1	Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML. Leukemia, 2022, 36, 656-663.	3.3	6
2	Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study. Leukemia and Lymphoma, 2021, 62, 438-445.	0.6	5
3	Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies. Blood Cancer Discovery, 2021, 2, 250-265.	2.6	19
4	Chronic myelomonocytic leukemia diagnosis and management. Leukemia, 2021, 35, 1552-1562.	3.3	18
5	Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia. Leukemia, 2021, 35, 2739-2751.	3.3	10
6	Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights. Annals of Oncology, 2021, 32, 1046-1048.	0.6	15
7	Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers. HemaSphere, 2021, 5, e632.	1.2	10
8	Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML. Blood Advances, 2021, 5, 5258-5268.	2.5	12
9	Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations. Blood, 2020, 135, 1032-1043.	0.6	11
10	The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. Nature Communications, 2020, 11, 1044.	5.8	81
11	A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Haematologica, 2019, 104, 1565-1571.	1.7	39
12	Exome analysis of treatmentâ€related <scp>AML</scp> after <scp>APL</scp> suggests secondary evolution. British Journal of Haematology, 2019, 185, 984-987.	1.2	1
13	Abstract PL02-03: The zinc-finger degrome. , 2019, , .		0
14	Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group. Haematologica, 2018, 103, 822-829.	1.7	36
15	Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations. Leukemia, 2018, 32, 2008-2081.	3.3	18
16	Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia. Leukemia, 2018, 32, 1856-1860.	3.3	7
17	The MLL recombinome of acute leukemias in 2017. Leukemia, 2018, 32, 273-284.	3.3	527
18	Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis. Leukemia and Lymphoma, 2018, 59, 1742-1745.	0.6	6

#	Article	IF	Citations
19	Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science, 2018, 362, .	6.0	320
20	Myelodysplastic syndrome (<scp>MDS</scp>) with isolated trisomy 8: a type of <scp>MDS</scp> frequently associated with myeloproliferative features? A report by the Groupe Francophone des MyÃ©lodysplasies. British Journal of Haematology, 2018, 182, 843-850.	1.2	18
21	Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. EBioMedicine, 2018, 31, 174-181.	2.7	72
22	Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia. Leukemia, 2018, 32, 2066-2069.	3.3	4
23	Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. Bone Marrow Transplantation, 2017, 52, 539-543.	1.3	30
24	TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia. Clinical Cancer Research, 2017, 23, 6325-6335.	3.2	64
25	Copy-number analysis identified new prognostic marker in acute myeloid leukemia. Leukemia, 2017, 31, 555-564.	3.3	34
26	Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2017, 35, 185-193.	0.8	227
27	BACH2 promotes indolent clinical presentation in WaldenstrÃ¶m macroglobulinemia. Oncotarget, 2017, 8, 57451-57459.	0.8	2
28	Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood, 2016, 127, 2451-2459.	0.6	198
29	A randomized phase II trial of azacitidine +/- epoetin-Â in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. Haematologica, 2016, 101, 918-925.	1.7	55
30	Assessment of Minimal Residual Disease in Standard-Risk AML. New England Journal of Medicine, 2016, 375, e9.	13.9	32
31	Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. Blood, 2016, 127, 749-760.	0.6	36
32	Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists. Expert Review of Hematology, 2016, 9, 1189-1202.	1.0	19
33	Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders. Orphanet Journal of Rare Diseases, 2016, 11, 49.	1.2	86
34	Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial. Haematologica, 2016, 101, 328-335.	1.7	97
35	Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine. Leukemia, 2016, 30, 1416-1418.	3.3	16
36	Genomic Landscape of CXCR4 Mutations in WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2016, 22, 1480-1488.	3.2	102

#	Article	IF	Citations
37	Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia, 2016, 30, 897-905.	3.3	109
38	Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia. Leukemia, 2016, 30, 999-1002.	3.3	86
39	UnlikeASXL1andASXL2mutations,ASXL3mutations are rare events in acute myeloid leukemia with t(8;21). Leukemia and Lymphoma, 2016, 57, 199-200.	0.6	19
40	De Novo and Secondary Acute Myeloid Leukemia, Real World Data on Outcomes from the French Nord-Pas-De-Calais Picardie Acute Myeloid Leukemia Observatory. Blood, 2016, 128, 4013-4013.	0.6	4
41	TP53 Mutation in Waldenstrom Macroglobulinemia. Blood, 2016, 128, 4092-4092.	0.6	1
42	Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases. Blood, 2016, 128, 2861-2861.	0.6	0
43	B7â€H3 protein expression in acute myeloid leukemia. Cancer Medicine, 2015, 4, 1879-1883.	1.3	32
44	Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood, 2015, 126, 1214-1223.	0.6	157
45	EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. Blood, 2015, 126, 1930-1939.	0.6	76
46	Incidence of <scp>ATRX</scp> mutations in myelodysplastic syndromes, the value of microcytosis. American Journal of Hematology, 2015, 90, 737-738.	2.0	15
47	Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia. Oncotarget, 2015, 6, 22812-22821.	0.8	45
48	French consensus on myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia: diagnosis, classification and treatment. Hematologie, 2015, 21, 46-59.	0.0	0
49	Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes. Leukemia Research, 2015, 39, 1214-1219.	0.4	2
50	Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. Haematologica, 2015, 100, 780-785.	1.7	42
51	Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia. Haematologica, 2015, 100, e196-e199.	1.7	16
52	Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group. Leukemia Research, 2015, 39, 1443-1447.	0.4	9
53	A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM. Blood, 2015, 126, 2872-2872.	0.6	1
54	IDH1/2but notDNMT3Amutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget, 2015, 6, 42345-42353.	0.8	92

#	Article	IF	Citations
55	French consensus on myelodysplasic syndrome and chronic myelomonocytic leukemia: diagnostic, classification and treatment 2015 update by the Myelodysplasia French Group. Hematologie, 2015, 21, 28-45.	0.0	1
56	MDS with Isolated Trisomy 8. a Type of MDS Frequently Associated with Myeloproliferative Features? A Report from the GFM. Blood, 2015, 126, 2881-2881.	0.6	0
57	Correlation Between Bone Marrow Dysplasia and Genomic Profile in De Novo Acute Myeloid Leukemia (AML): A Study By the ALFA Group. Blood, 2015, 126, 2568-2568.	0.6	0
58	NPM1 Minimal Residual Disease As Prognostic and Predictive Factor in Young Adults with Acute Myeloid Leukemia: a Study By the French ALFA Group. Blood, 2015, 126, 2581-2581.	0.6	1
59	Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1â€RUNX1T1 fusion quantification on genomic DNA. American Journal of Hematology, 2014, 89, 610-615.	2.0	21
60	Serum 2-Hydroxyglutarate Production in IDH1- and IDH2-Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2014, 32, 297-305.	0.8	109
61	Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse. American Journal of Hematology, 2014, 89, 399-403.	2.0	22
62	Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood, 2014, 124, 1445-1449.	0.6	105
63	Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leukemia Research, 2014, 38, 751-755.	0.4	141
64	SET-NUP214 is a recurrent Î³Î´ lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL. Blood, 2014, 123, 1860-1863.	0.6	40
65	Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group. Blood, 2014, 124, 2327-2327.	0.6	1
66	Final Analysis of the ALFA 0701 Study. Blood, 2014, 124, 376-376.	0.6	20
67	Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA). Blood, 2014, 124, 482-482.	0.6	2
68	NPM1 Expression Level and a CRBN Polymorphism Are Able to Predict the Rate of Response to Lenalidomide in Non Del(5q) Lower Risk MDS Patients Resistant to Erythropoiesis-Stimulating Agents: The GFM Experience. Blood, 2014, 124, 533-533.	0.6	1
69	Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial. Oncotarget, 2014, 5, 916-932.	0.8	47
70	Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines. Oncotarget, 2014, 5, 4384-4391.	0.8	17
71	MRD assessed byWT1andNPM1transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget, 2014, 5, 6280-6288.	0.8	71
72	Incidence of Atrx Mutations in Myelodysplastic Syndromes (MDS). Blood, 2014, 124, 4629-4629.	0.6	0

#	Article	IF	Citations
73	Absolute Quantification of EVI1 Overexpression in Acute Myeloid Leukemia By RQ-PCR Analysis : A Study of the ALFA Group. Blood, 2014, 124, 1062-1062.	0.6	12
74	Detection of TP53 Mutations in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). a Comparison Between a Functional Method (FASAY) and Next Generation Sequencing (NGS). Blood, 2014, 124, 3266-3266.	0.6	1
75	Prognostic Analysis of GATA2 Mutations in CEBPA-Mutated Acute Myeloid Leukemia. Blood, 2014, 124, 2360-2360.	0.6	0
76	Quantification of JAK2V617F mutation by next-generation sequencing technology. American Journal of Hematology, 2013, 88, 536-537.	2.0	9
77	Clonal architecture of chronic myelomonocytic leukemias. Blood, 2013, 121, 2186-2198.	0.6	232
78	Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood, 2013, 121, 2213-2223.	0.6	313
79	The MLL recombinome of acute leukemias in 2013. Leukemia, 2013, 27, 2165-2176.	3.3	393
80	Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. Journal of Clinical Oncology, 2013, 31, 2428-2436.	0.8	462
81	P-023 Incidence and prognostic value of TP53 mutations in IPSS low and INT 1 (lower risk) MDS with del 5q. Leukemia Research, 2013, 37, S32-S33.	0.4	1
82	P-087 SAA associated to a del(5)(q15q31) clone not involving EGR1: Progression of this clone contrasting with SAA improvement under immunosuppressive therapy. Leukemia Research, 2013, 37, S61.	0.4	0
83	SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia, 2013, 27, 1401-1403.	3.3	102
84	Superior Long-Term Outcome With Idarubicin Compared With High-Dose Daunorubicin in Patients With Acute Myeloid Leukemia Age 50 Years and Older. Journal of Clinical Oncology, 2013, 31, 321-327.	0.8	68
85	Neurofibromatosisâ€1 gene deletions and mutations in de novo adult acute myeloid leukemia. American Journal of Hematology, 2013, 88, 306-311.	2.0	43
86	Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. American Journal of Hematology, 2013, 88, 948-954.	2.0	45
87	MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood, 2013, 121, 4504-4511.	0.6	214
88	BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood, 2013, 122, 3169-3177.	0.6	169
89	Acute myeloid leukemia with translocation t(3;5): new molecular insights. Haematologica, 2013, 98, e52-e54.	1.7	13
90	The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia. Medicine (United States), 2013, 92, e1-e9.	0.4	80

#	Article	IF	Citations
91	New-generation sequencing (NGS) in hematologic oncology laboratories. Hematologie, 2013, 19, 112-122.	0.0	2
92	Linezolid induces ring sideroblasts. Haematologica, 2013, 98, e138-e140.	1.7	21
93	The B7-H3 Protein In Acute Myeloid Leukemia. Blood, 2013, 122, 2620-2620.	0.6	1
94	Prognostic Factors Of Response and Survival To Azacitidine (AZA) +/- EPO In RBC Transfusion Dependent (TD) IPSS Low and Int-1 (LR) MDS Resistant To EPO, With Particular Emphasis Of Genetic Lesions: A Study By The GFM. Blood, 2013, 122, 658-658.	0.6	1
95	Minimal Residual Disease Monitoring In t(8;21) Acute Myeloid Leukemia Based On RUNX1-RUNX1T1 Fusion Quantification On Genomic DNA. Blood, 2013, 122, 1353-1353.	0.6	0
96	Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing. Blood, 2013, 122, 740-740.	0.6	0
97	Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival. Haematologica, 2012, 97, 890-894.	1.7	85
98	MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations. Blood, 2012, 120, 2719-2722.	0.6	68
99	Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial. Leukemia Research, 2012, 36, 1112-1118.	0.4	9
100	Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis. Leukemia Research, 2012, 36, 1330-1333.	0.4	9
101	BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients. Oncotarget, 2012, 3, 490-501.	0.8	75
102	Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia, 2012, 26, 1247-1254.	3.3	119
103	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood, 2012, 119, 3211-3218.	0.6	220
104	Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. Leukemia Research, 2012, 36, 316-323.	0.4	50
105	TOP3A, a new partner gene fused to MLL in an adult patient with de novo acute myeloid leukaemia. British Journal of Haematology, 2012, 157, 128-131.	1.2	5
106	MYD88 L265P Mutation in Waldenstrom's Macroglogulinemia. Blood, 2012, 120, 1307-1307.	0.6	2
107	Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine. Blood, 2012, 120, 1706-1706.	0.6	3
108	Genome Wide SNP Array (SNPa) Analysis Reveals Clonal Evolution During Clinical Course in Waldenstrom's Macroglobulinemia (WM). Blood, 2012, 120, 297-297.	0.6	2

#	Article	IF	Citations
109	Comprehensive Genetic Screening of Chronic Myelomonocytic Leukemias (CMML). Blood, 2012, 120, 3811-3811.	0.6	1
110	High DNA Methyltransferase DNMT3B Levels: A Poor Prognostic Marker in Acute Myeloid Leukemia. PLoS ONE, 2012, 7, e51527.	1.1	58
111	BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes. Blood, 2012, 120, 1697-1697.	0.6	0
112	Incidence and Prognostic Value of TP53 Mutations in Lower Risk MDS with Del 5q.. Blood, 2012, 120, 2809-2809.	0.6	0
113	B-Cell-Specific Transcription Factor BACH2 Involved in the Clinical Behavior Heterogeneity of Waldenstroì^m Macroglobulinemia. Blood, 2012, 120, 1288-1288.	0.6	0
114	Minimal Residual Disease Assessed by WT1 Expression and NPM1 Mutations Specific RQ-PCR Assays Identifies Patients with Distinct Outcomes in the ALFA 0701 Trial and Is Decreased by Treatment with Gemtuzumab Ozogamicin. Blood, 2012, 120, 659-659.	0.6	4
115	Two Distinct Mechanisms Contribute to Granulomonocytic Hyperplasia in Chronic Myelomonocytic Leukemias (CMML). Blood, 2012, 120, 309-309.	0.6	0
116	Effector CD4+CD45RAâ^'CD25brightFoxp3bright Regulatory T Cell (eTreg) Distribution Is Significantly Impaired in Chronic Myelomonocytic Leukemia (CMML) and Correlates with TET 2 Mutational Status.. Blood, 2012, 120, 2808-2808.	0.6	0
117	Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia. Leukemia, 2011, 25, 1918-1921.	3.3	12
118	Implication of IDH1 and IDH2 gene mutations in acute myeloid leukemia. Hematologie, 2011, 17, 132-144.	0.0	0
119	Wilmsâ€™ Tumor 1 (WT1) and acute leukemia. Hematologie, 2011, 17, 40-60.	0.0	0
120	Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood, 2011, 117, 3696-3697.	0.6	36
121	Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood, 2011, 118, 1754-1762.	0.6	52
122	Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood, 2011, 118, 3824-3831.	0.6	187
123	Clonal expansion of T cells in patients with eosinophilic lung disease. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1506-1508.	2.7	14
124	Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): Evolution on hypomethylating agent therapy. Leukemia Research, 2011, 35, e203-e205.	0.4	5
125	Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial. Blood, 2011, 118, 410-410.	0.6	0
126	SNP Array Analysis in Acute Myeloid Leukemia Reveals Frequent and Recurrent Acquired Genetic Alterations Linked to Prognosis: a Study of the ALFA Group. Blood, 2011, 118, 2533-2533.	0.6	0

#	Article	IF	Citations
127	Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood, 2010, 116, 1132-1135.	0.6	121
128	Which AML subsets benefit from leukemic cell priming during chemotherapy? Longâ€term analysis of the ALFAâ€9802 GMâ€CSF study. Cancer, 2010, 116, 1725-1732.	2.0	23
129	Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. British Journal of Haematology, 2010, 151, 460-468.	1.2	64
130	Extensive mutational status of genes and clinical outcome in pediatric acute myeloid leukemia. Leukemia, 2010, 24, 205-209.	3.3	7
131	Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies. Leukemia, 2010, 24, 476-480.	3.3	19
132	Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience. Leukemia, 2010, 24, 1386-1388.	3.3	20
133	Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2010, 28, 3717-3723.	0.8	189
134	Deletion of the Tumor Suppressor Gene NF1 Is Found In 3.5% of 485 De Novo Adult Myeloid Leukemia and Is Correlated with Unfavourable Cytogenetic: On Behalf of the ALFA Group. Blood, 2010, 116, 4171-4171.	0.6	0
135	Prognostic Impact of Wilms Tumor 1 Single Nucleotide Polymorphism rs16754 In Older Patients with Acute Myeloid Leukemia. Blood, 2010, 116, 2701-2701.	0.6	1
136	Place deÂlaÂbiologie molÃ©culaire dansÂlâ€™Ã©valuation pronostique desÂpatients atteints deÂleucÃ©mie aiguÃ« myÃ©loÃ¯de. Hematologie, 2009, 15, 426-443.	0.0	0
137	Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia. Cancer, 2009, 115, 3719-3727.	2.0	75
138	Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. Leukemia, 2009, 23, 804-806.	3.3	45
139	New insights to the MLL recombinome of acute leukemias. Leukemia, 2009, 23, 1490-1499.	3.3	363
140	Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study. Journal of Clinical Oncology, 2009, 27, 5195-5201.	0.8	409
141	Slow relapse in acute myeloid leukemia with inv(16) or t(16;16). Haematologica, 2009, 94, 1466-1467.	1.7	7
142	The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood, 2009, 113, 5090-5093.	0.6	87
143	High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood, 2009, 113, 5583-5587.	0.6	162
144	The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication. Blood, 2009, 114, 4601-4602.	0.6	19

#	Article	IF	Citations
145	Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML).. Blood, 2009, 114, 163-163.	0.6	4
146	Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia. Genes Chromosomes and Cancer, 2008, 47, 915-918.	1.5	25
147	Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia, 2008, 22, 915-931.	3.3	319
148	Recurrent in-frame insertion in C/EBPÎ± TAD2 region is a polymorphism without prognostic value in AML. Leukemia, 2008, 22, 655-657.	3.3	12
149	JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia, 2008, 22, 1454-1455.	3.3	45
150	Incidence and Prognostic Impact of SNPs Regulating PU.1 Gene Expression in AML. Blood, 2008, 112, 2949-2949.	0.6	0
151	Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation. Leukemia, 2007, 21, 2376-2377.	3.3	13
152	Real-Time Quantitative PCR (RQ-PCR) Detection of Minimal Residual Disease (MRD) by Optimized WT1 Assay To Enhance Risk Stratification in Acute Myeloid Leukemia (AML): A European LeukemiaNet Study.. Blood, 2007, 110, 542-542.	0.6	4
153	Evaluation of Minimal Residual Disease Based on NPM1 Mutations in AML with Intermediate Risk Cytogenetics: A Prospective Study of 36 Patients.. Blood, 2007, 110, 2847-2847.	0.6	0
154	Prognostic Value of Minimal Residual Disease by Real-Time Quantitative PCR in AML with CBFB-MYH11 Rearrangement: The French Experience.. Blood, 2007, 110, 3496-3496.	0.6	0
155	Cooperation of activating Ras/rtk signal transduction pathway mutations and inactivating myeloid differentiation gene mutations in M0 AML: a study of 45 patients. Leukemia, 2006, 20, 433-436.	3.3	18
156	High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia, 2006, 20, 2067-2070.	3.3	64
157	High WT1 Expression After Induction Therapy Predicts High Risk of Relapse and Death in Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2006, 24, 1507-1515.	0.8	152
158	Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood, 2005, 106, 3618-3620.	0.6	208